Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 11/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29775782 | 1.00 | KDM2B (0.42) | KDM2BSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23491166 | 0.84 | SMN1; SMN2 (0.42) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19814466 | 0.81 | GABRR1 (0.38) | KDM2B | |
| SCHEMBL28331096 | 0.81 | GABRR1 (0.38) | KDM2B | |
| SCHEMBL19814581 | 0.81 | GABRR1 (0.38) | KDM2B | |
| SCHEMBL23269564 | 0.80 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23269568 | 0.80 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19781542 | 0.80 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23269576 | 0.80 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19779684 | 0.80 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3798217-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-04-19 | — | — | US | disclosed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | disclosed |
| EP-3798217-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-03-31 | — | — | EP | disclosed |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-10 | — | — | US | disclosed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | disclosed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | KDM2B 3060/4885SLC6A2 4172/4885SLC6A4 3759/4885 |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | KDM2B 3060/4885SLC6A2 4172/4885SLC6A4 3759/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | KDM2B 2947/4885SLC6A2 3639/4885SLC6A4 3110/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | KDM2B 2947/4885SLC6A2 3639/4885SLC6A4 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.